Top Markets
#1 ONFA ONFA +225.03%
#2 Resolv wstUSR Resolv wstUSR +198.11%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 NKN NKN +36.62%
#6 DeAgentAI DeAgentAI +32.88%
#7 StakeStone StakeStone +27.06%
#8 BLOCKv BLOCKv +26.09%
#9 KONET KONET +22.11%
#10 OpenVPP OpenVPP +21.99%
Coin of the day
ONFA ONFA
設定
言語
日本
通貨
USD
テーマ
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
株式のランク #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
株価
$0.5275
時価総額
$1.25M
変化（1日）
-3.56%
変化（1年）
-83.77%
国
US
取引 Ensysce Biosciences, Inc. (ENSC)

カテゴリー

Healthcare
Ensysce Biosciences, Inc.（ENSC）の配当利回りの履歴
Ensysce Biosciences, Inc.（銘柄コード: ENSC）の配当利回り（TTM）は2023-12-31時点で0.00%です。
過去5年間の平均配当利回り: 11,707.83%
Ensysce Biosciences, Inc.（ENSC）の2017から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
2026 (TTM) 0.00% -100.00%
2024 2,039.30% 0.00%
2023 0.00% -100.00%
2022 3.76% -99.99%
2021 56,496.11% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.72%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
0.48%
US
UCB SA UCB SA
UCB SA
UCB.BR
0.48%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.03%
AU